Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, et al. The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia. 2020;34(11):2964-2980.

Zanazzi G, Liechty BL, Pendrick D, Krasnozhen-Ratush O, Snuderl M, Allen JC, et al. Diffuse midline glioma with novel, potentially targetable, fusion. Cold Spring Harb Mol Case Stud. 2020;6(5).

Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, et al. Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. J Clin Invest. 2020;130(5):2220-2236.

Patel SS, Weinberg OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95(6):718-722.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, et al. Publisher Correction: Building an international consortium for tracking coronavirus health status. Nat Med. 2020;26(8):1309.

Chadburn A, Chen Y-, Nayar R, Young A, Sumpter I, Lee C, et al. Limited Tissue Samples: Hematopoietic Lesions - Three Case Examples of Judicious Use of Limited Material. Acta Cytol. 2020;64(1-2):71-80.

Xu B, Barbieri AL, Bishop JA, Chiosea SI, Dogan S, Di Palma S, et al. Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG): An International Interobserver Study. Am J Surg Pathol. 2020;44(4):545-552.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, et al. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica. 2020;105(5):e221-e224.

Armache A, Yang S, de Paz AM, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature. 2020;583(7818):852-857.

Storch EK, Rogerson B, Eder AF. Trend in ABO-incompatible RBC transfusion-related fatalities reported to the FDA, 2000-2019. Transfusion. 2020;60(12):2867-2875.